N
Noriko Motoi
Researcher at Japanese Foundation for Cancer Research
Publications - 202
Citations - 9704
Noriko Motoi is an academic researcher from Japanese Foundation for Cancer Research. The author has contributed to research in topics: Lung cancer & Adenocarcinoma. The author has an hindex of 32, co-authored 183 publications receiving 7911 citations. Previous affiliations of Noriko Motoi include Memorial Sloan Kettering Cancer Center & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Jonathan F. Bean,Cameron Brennan,Jin-Yuan Shih,Gregory J. Riely,Gregory J. Riely,Agnes Viale,Lu Wang,Dhananjay Chitale,Noriko Motoi,Noriko Motoi,Janos Szoke,Stephen Broderick,Marissa Balak,Wen Cheng Chang,Chong-Jen Yu,Adi F. Gazdar,Harvey I. Pass,Valerie W. Rusch,William L. Gerald,Shiu Feng Huang,Pan-Chyr Yang,Vincent Miller,Vincent Miller,Marc Ladanyi,Chih-Hsin Yang,William Pao,William Pao +26 more
TL;DR: Analysis of tumor samples from multiple independent patient cohorts and array-based comparative genomic hybridization suggest that MET amplification occurs independently of EGFRT790M mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib.
Journal ArticleDOI
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Kerby Shedden,Jeremy M. G. Taylor,Steven A. Enkemann,Ming-Sound Tsao,Timothy J. Yeatman,William L. Gerald,Steven A. Eschrich,Igor Jurisica,Thomas J. Giordano,David E. Misek,Andrew C. Chang,Chang-Qi Zhu,Daniel Strumpf,Samir M. Hanash,Frances A. Shepherd,Keyue Ding,Lesley Seymour,Katsuhiko Naoki,Nathan A. Pennell,Barbara A. Weir,Roeland Verhaak,Christine Ladd-Acosta,Todd R. Golub,Michael Gruidl,Anupama Sharma,Janos Szoke,Maureen F. Zakowski,Valerie W. Rusch,Mark G. Kris,Agnes Viale,Noriko Motoi,William D. Travis,Barbara A. Conley,Venkatraman E. Seshan,Matthew Meyerson,Matthew Meyerson,Rork Kuick,Kevin K. Dobbin,Tracy Lively,James W. Jacobson,David G. Beer +40 more
TL;DR: A large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas, providing the largest available set of microarray data with extensive pathological and clinical annotation for lungAdenocARCinomas.
Journal ArticleDOI
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
Akihiko Yoshizawa,Noriko Motoi,Noriko Motoi,Gregory J. Riely,C.S. Sima,William L. Gerald,Mark G. Kris,Bernard J. Park,Valerie W. Rusch,William D. Travis +9 more
TL;DR: The proposed IASLC/ATS/ERS classification of lung adenocarcinoma identifies histological categories with prognostic differences that may be helpful in identifying candidates for adjunctive therapy and raises the need for further studies to determine whether this adjustment in measuring tumor size could impact TNM staging for small adenoplastomas.
Journal ArticleDOI
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Sizhi Paul Gao,Kevin G. Mark,Kenneth Leslie,William Pao,Noriko Motoi,William L. Gerald,William D. Travis,William G. Bornmann,Darren R. Veach,Bayard D. Clarkson,Jacqueline Bromberg +10 more
TL;DR: In this article, the authors found that persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas.
Journal ArticleDOI
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
Kentaro Inamura,Kengo Takeuchi,Yuki Togashi,Satoko Hatano,Hironori Ninomiya,Noriko Motoi,Mingyon Mun,Yukinori Sakao,Sakae Okumura,Ken Nakagawa,Manabu Soda,Young Lim Choi,Hiroyuki Mano,Yuichi Ishikawa +13 more
TL;DR: EML4-ALK-positive tumors may form a distinct entity among lung adenocarcinomas, characterized by young onset, acinar histology, no or rare mutations in EGFR, KRAS, and TP53, and a TTF-1 cell lineage, all in agreement with the prevalence in non- or light smokers.